Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Exclusion Criteria

• •Unconsciousness
• •Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
• •Severe illness with life expectancy less than 6 months.
• •Known severe kidney disorder.
• •Current known alcohol or illicit drug abuse or dependence.
• •Pregnant or breast-feeding.
• •Treatment with acetazolamide and methotrexate is not permitted during the infusion
• •Participation in a previous clinical study within 7 days.